{"Abstract": [0], "Bladder": [1], "cancer": [2, 8, 41, 83], "remains": [3], "a": [4, 50, 56, 87, 231], "leading": [5], "cause": [6], "of": [7, 20, 36, 49, 72, 89, 119, 197, 209], "death": [9], "worldwide": [10], "and": [11, 24, 65, 92, 97, 101, 113, 115, 139, 149, 163, 182, 201, 215], "is": [12, 43, 66, 131, 234], "associated": [13, 67], "with": [14, 46, 68, 121, 171], "substantial": [15], "impacts": [16], "on": [17], "patient": [18], "quality": [19], "life,": [21], "morbidity,": [22], "mortality,": [23], "cost": [25], "to": [26, 60, 86, 143, 206, 222, 228], "the": [27, 34, 132, 198, 207, 224], "healthcare": [28], "system.": [29], "Gross": [30], "hematuria": [31], "frequently": [32], "precedes": [33], "diagnosis": [35], "bladder": [37, 40, 51, 82, 188], "cancer.": [38], "Non-muscle-invasive": [39], "(NMIBC)": [42], "managed": [44], "initially": [45], "transurethral": [47], "resection": [48], "tumor": [52, 202], "(TURBT),": [53], "followed": [54], "by": [55], "risk": [57, 141], "stratified": [58], "approach": [59], "adjuvant": [61], "intravesical": [62], "therapy": [63, 162], "(IVe),": [64], "an": [69, 235], "overall": [70], "survival": [71], "90%.": [73], "However,": [74], "cure": [75], "rates": [76], "remain": [77], "lower": [78], "for": [79, 136], "muscle": [80], "invasive": [81], "(MIBC)": [84], "owing": [85], "variety": [88], "factors.": [90], "NMIBC": [91, 142], "MIBC": [93, 120], "groupings": [94], "are": [95, 179], "heterogeneous": [96], "have": [98, 167, 204], "unique": [99], "pathological": [100], "molecular": [102, 117], "characteristics.": [103], "Indeed,": [104], "The": [105], "Cancer": [106], "Genome": [107], "Atlas": [108], "project": [109], "identified": [110], "genetic": [111], "drivers": [112], "luminal": [114], "basal": [116], "subtypes": [118], "distinct": [122], "treatment": [123, 135, 233], "responses.": [124], "For": [125, 174], "NMIBC,": [126], "IVe": [127, 160, 165], "immunotherapy": [128], "(primarily": [129], "BCG)": [130], "gold": [133], "standard": [134], "high": [137, 140], "grade": [138], "reduce": [144], "or": [145, 187], "prevent": [146], "both": [147], "recurrence": [148], "progression": [150], "after": [151], "initial": [152], "TURBT;": [153], "novel": [154], "trials": [155], "incorporate": [156], "immune": [157, 210], "checkpoint": [158, 211], "inhibitors.": [159], "gene": [161], "combination": [164], "chemotherapy": [166], "recently": [168], "been": [169], "completed,": [170], "promising": [172], "results.": [173], "localized": [175], "MIBC,": [176], "essential": [177], "goals": [178], "improving": [180], "care": [181], "reducing": [183], "morbidity": [184], "following": [185], "cystectomy": [186], "preserving": [189], "strategies.": [190], "In": [191], "metastatic": [192], "disease,": [193], "advances": [194], "in": [195], "understanding": [196], "genomic": [199], "landscape": [200], "microenvironment": [203], "led": [205], "implementation": [208], "inhibitors,": [212], "targeted": [213], "treatments,": [214], "antibody-drug": [216], "conjugates.": [217], "Defining": [218], "better": [219], "selection": [220], "criteria": [221], "identify": [223], "patients": [225], "most": [226], "likely": [227], "benefit": [229], "from": [230], "specific": [232], "urgent": [236], "need.": [237]}